A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration ‐resistant prostate cancer
ConclusionsTreatment with abiraterone acetate without steroids is feasible, although clinically significant adverse events can occur in a minority of patients. The use of abiraterone acetate without prednisone should be balanced with the potential for toxicity and requires close monitoring.
Source: Cancer - Category: Cancer & Oncology Authors: Rana R. McKay,
Lillian Werner,
Susanna J. Jacobus,
Alexandra Jones,
Elahe A. Mostaghel,
Brett T. Marck,
Atish D. Choudhury,
Mark M. Pomerantz,
Christopher J. Sweeney,
Susan F. Slovin,
Michael J. Morris,
Philip W. Kantoff,
Mary ‐Ellen Taplin Tags: Original Article Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Hypertension | Ketoconazole | Potassium | Prednisone | Prostate Cancer | Radiography | Study | Toxicology